Contract 75A50124C00061
Partner Therapeutics, Inc. · Department Of Health And Human Services · September 24, 2024
Partner Therapeutics, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 24, 2024 for $12.99 million of work in research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology). Performance is in Lexington, MA. It was awarded under full and open competition. The contract has been modified 3 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on August 8, 2025.
Contract details
- PIID
- 75A50124C00061
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Competed Under Sap
- NAICS
- 541715 · Research And Development In The Physical, Engineering, And Life Sciences (Except Nanotechnology And Biotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- Place of performance
- Lexington, MA
- First action
- September 24, 2024
- Latest action
- August 8, 2025
Description
THE PURPOSE OF THIS NO COST MODIFICATION IS TO UPDATE SECTION G.1 CONTRACTING OFFICER FROM REBECCA FOSTER TO AUDREY GLOVER.
Modification timeline
-
August 8, 2025Mod P00003$0
-
May 7, 2025Mod P00002PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFF$0
-
February 28, 2025Mod P00001PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFF$0
-
September 24, 2024Base awardPARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFF$12.99M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| The Emmes Company, Llc | Department Of Health And Human Services | April 1, 2026 | $771.5K |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $8.00M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $9.22M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $327.13M |
| The Brain Donor Project, Inc | Department Of Health And Human Services | April 1, 2026 | $1.27M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $20.43M |
Top contractors in NAICS 541715
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Fluor Marine Propulsion, Llc | 2 | $28.31B |
| 2 | California Institute Of Technology | 818 | $19.55B |
| 3 | Lockheed Martin Corp | 28 | $9.64B |
| 4 | The Aerospace Corporation | 393 | $8.97B |
| 5 | Lockheed Martin Corp | 23 | $7.69B |
| 6 | The Johns Hopkins University Applied Physics Laboratory Llc | 1,336 | $7.27B |
| 7 | Leidos Biomedical Research Inc | 167 | $6.23B |
| 8 | The Mitre Corporation | 398 | $6.07B |
| 9 | Lockheed Martin Corporation | 15 | $5.04B |
| 10 | Booz Allen Hamilton Inc | 169 | $4.28B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50124C00061?
Contract 75A50124C00061 is a federal contract awarded to Partner Therapeutics, Inc. by Department Of Health And Human Services on September 24, 2024 for $12.99 million of work classified under RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). It has been modified 3 times since the base award.
Who won contract 75A50124C00061?
Partner Therapeutics, Inc. won contract 75A50124C00061 from Department Of Health And Human Services.
How much is contract 75A50124C00061 worth?
Contract 75A50124C00061 has obligated $12.99 million to date, with a total potential value of $13.68 million if all options are exercised.